These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7528864)

  • 1. Prostate-specific antigen (PSA): its clinical value in prostatic disease.
    Dutkiewicz S; Witeska A
    Mater Med Pol; 1994; 26(1):21-4. PubMed ID: 7528864
    [No Abstract]   [Full Text] [Related]  

  • 2. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen testing. An essential guide to its use and meaning.
    Marks SH
    Adv Nurse Pract; 2001 Apr; 9(4):38-9, 43-4. PubMed ID: 12420434
    [No Abstract]   [Full Text] [Related]  

  • 4. Can percent free prostate-specific antigen reduce the need for prostate biopsy?
    Lieberman S
    Eff Clin Pract; 1999; 2(6):266-71. PubMed ID: 10788024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of complexed PSA for the early detection of prostate cancer.
    Fischer K; Loertzer H; Fornara P
    Anticancer Res; 2005; 25(3A):1591-6. PubMed ID: 16033065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].
    Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K
    Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of determining prostate specific antigen in follow-up of prostatic cancer].
    Sadeh AD; Mukamel E; Galili Y; Nussbaum B; Regev D; Servadio C
    Harefuah; 1993 Aug; 125(3-4):69-74, 128. PubMed ID: 7693556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000.
    Gray MA; Cooke RR; Weinstein P; Nacey JN
    Ann Clin Biochem; 2004 May; 41(Pt 3):207-12. PubMed ID: 15117434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice.
    Collins GN; Martin PJ; Wynn-Davies A; Brooman PJ; O'Reilly PH
    J Urol; 1997 May; 157(5):1744-7. PubMed ID: 9112518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostatic specific antigen in practice in 1997].
    Salomon L; Colombel M; Patard JJ; Chopin D; Abbou CC
    Ann Urol (Paris); 1998; 32(2):69-72. PubMed ID: 9599634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum chromogranin A in prostate cancer. Preliminary results].
    Reale MG; Marchei GG; Boccia S; Cristofoletti C; Caporossi E; Marchei M; Izzo P; Marchei P
    Minerva Med; 1999; 90(7-8):221-3. PubMed ID: 10719423
    [No Abstract]   [Full Text] [Related]  

  • 16. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
    Kato M; Okada K
    Hinyokika Kiyo; 1993 Mar; 39(3):221-3. PubMed ID: 7685140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    J Urol; 1997 Feb; 157(2):544-7. PubMed ID: 8996352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen and prostate cancer.
    Rosalki SB; Rutherford FJ
    Int J Clin Pract; 2000 Nov; 54(9):611-3. PubMed ID: 11220990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.